Proteomic profiling of plasma exosomes reveals CD82 involvement in the development of esophageal squamous cell carcinoma

Yang, Lifei; Salai, Adili; Sun, Xingming; Liu, Qing; Liu, Tao; Zhang, Qiqi; Tuerxun, Aerziguli; Tan, Yiyi; Lü, Xiaomei

doi:10.1016/j.jprot.2022.104662

Cited by 8 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We argue that the penalty imposed on collinearity by the stepwise regression process when building the model causes ethnic differences to become a valid variable. Previous studies have shown that the morbidity and mortality of ESCC are higher in Hazak than in Han patients, [3,4] and the differences in lifestyles such as diet between two nation groups may have contributed to this result. [23] In the study of Huiwu Li et al, it was found that there are differentially expressed genes between Hazak and Han patients.…”

Section: Discussionmentioning

confidence: 99%

“…[1,2] Xinjiang is an area with a high incidence of ESCC, and studies have shown that the morbidity and mortality of ESCC are higher in Hazak than in Han. [3,4] ESCC lacks effective therapeutic targets and prognostic biomarkers. Therefore, exploring the differences in biomarkers and prognosis between Hazak and Han patients with ESCC is of great significance for studying the pathogenesis of esophageal squamous cell carcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Construction of a prognostic model for radical esophagectomy based on immunohistochemical prognostic markers combined with clinicopathological factors

Wang

et al. 2023

Medicine

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) has a poor prognosis and lacks effective biomarkers to evaluate prognosis and treatment. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a protein highly expressed in ESCC tissues screened by isobaric tags for relative and absolute quantitation proteomics, which has significant prognostic value in a variety of malignant tumors, but its relationship with ESCC remains unclear. By immunohistochemical staining of 266 ESCC samples, we analyzed the relationship between GPNMB and ESCC. To explore how to improve the ability of ESCC prognostic assessment, we established a prognostic model of GPNMB and clinicopathological features. The results suggest that GPNMB expression is generally positive in ESCC tissues and is significantly associated with poorer differentiation, more advanced American Joint Council on Cancer (AJCC) stage, and higher tumor aggressiveness (P < .05). Multivariate Cox analysis indicated that GPNMB expression was an independent risk factor for ESCC patients. A total of 188 (70%) patients were randomly selected from the training cohort and the four variables were automatically screened by stepwise regression based on the AIC principle: GPNMB expression, nation, AJCC stage and nerve invasion. Through the weighted term, we calculate the risk score of each patient, and by drawing the receiver operating characteristic curve, we show that the model has good prognostic evaluation performance. The stability of the model was verified by test cohort. Conclusion: GPNMB is a prognostic marker consistent with the characteristics of tumor therapeutic targets. For the first time, we constructed a prognostic model combining immunohistochemical prognostic markers and clinicopathological features in ESCC, which showed higher prognostic efficacy than AJCC staging system in predicting the prognosis of ESCC patients in this region.Abbreviations: AJCC = American Joint Council on Cancer, AUC = area under the curve, ESCC = esophageal squamous cell carcinoma, GPNMB = glycoprotein nonmetastatic melanoma protein B, IHC = immunohistochemical, ITRAQ = isobaric tags for relative and absolute quantitation, OS = overall survival, ROC curve = receiver operating characteristic curve.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Construction of a prognostic model for radical esophagectomy based on immunohistochemical prognostic markers combined with clinicopathological factors

Wang

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…In addition, the exosome bilayer also contains specific proteins that reflect its parent cells to a large extent. These proteins include adhesion molecules, membrane transport molecules, cytoskeleton molecules, cytoplasmic enzymes, signal transduction proteins and cell-specific antigens [ [112] , [113] , [114] , [115] , [116] ]. Currently, studies have shown that almost all cells can transfer specific nucleic acids, proteins and lipids between cells by secreting exosomes to play an important role in intercellular communication and play a key role in the maintenance of protein and lipid homeostasis [ 117 , 118 ].…”

Section: Exosomes and Exosomal Mirnasmentioning

confidence: 99%

Exosomes and exosomal miRNAs: A new avenue for the future treatment of rheumatoid arthritis

Liu,

Jiang,

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Furthermore, exosomal PKM2 was shown to be heavily engaged in cisplatin resistance in non‐small cell lung cancer (Wang, Zhao, et al, 2021). In our own study (Yang, Zheng, et al, 2021) from esophageal squamous cell carcinoma (ESCC), PKM2 was also identified to be included in exosomes derived from the peripheral blood of patients with ESCC (Yang, Salai, et al, 2022). We found that exosomal PKM2 accelerates the proliferation, migration, and invasion of ESCC cells in vitro.…”

Section: Exosomal Pkm2mentioning

confidence: 99%

Positioning determines function: Wandering PKM2 performs different roles in tumor cells

He,

Liang,

Tan

et al. 2023

Cell Biology International

Self Cite

View full text Add to dashboard Cite

Short for pyruvate kinase M2 subtype, PKM2 can be said of all‐round player that is notoriously known for its metabolic involvement in glycolysis. Holding a dural role as a metabolic or non‐metabolic (kinase) enzyme, PKM2 has drawn extensive attention over its biological roles implicated in tumor cells, including proliferation, migration, invasion, metabolism, and so on. wandering PKM2 can be transboundary both intracellularly and extracellularly. Specifically, PKM2 can be nuclear, cytoplasmic, mitochondrial, exosomal, or even circulate within the body. Importantly, PKM2 can function as an RNA‐binding protein (RBP) to self‐support its metabolic function. Despite extensive investigations or reviews available surrounding the biological roles of PKM2 from different angles in tumor cells, little has been described regarding some novel role of PKM2 that has been recently found, including, for example, acting as RNA‐binding protein, protection of Golgi apparatus, and remodeling of microenvironment, and so forth. Given these findings, in this review, we summarize the recent advancements made in PKM2 research, mainly from non‐metabolic respects. By the way, PKM1, another paralog of PKM2, seems to have been overlooked or under‐investigated since its discovery. Some recent discoveries made about PKM1 are also preliminarily mentioned and discussed.

show abstract

Proteomic profiling of plasma exosomes reveals CD82 involvement in the development of esophageal squamous cell carcinoma

Cited by 8 publications

References 43 publications

Construction of a prognostic model for radical esophagectomy based on immunohistochemical prognostic markers combined with clinicopathological factors

Construction of a prognostic model for radical esophagectomy based on immunohistochemical prognostic markers combined with clinicopathological factors

Exosomes and exosomal miRNAs: A new avenue for the future treatment of rheumatoid arthritis

Positioning determines function: Wandering PKM2 performs different roles in tumor cells

Contact Info

Product

Resources

About